Zyuds Lifesciences receives USFDA approval for DMD treatment drug
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
The product will be launched in Q1FY26
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
Padmanabhan brings over two decades of extensive experience in FMCG sector
The company does not expect this development to have any material impact on the current business operations
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Subscribe To Our Newsletter & Stay Updated